
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Don’t miss our latest news! Sign up today for our free newsletter.
By continuing to use our site, you agree to our Private Policy and Terms of Use.
A study of 1,288 HIV-positive and HIV-negative men from four U.S. cities shows that long-term treatment with Epivir or Zerit is linked to an increased risk of insulin resistance, with longer time on the drugs resulting in a greater risk for the prediabetic condition. The study uncovered no link between insulin resistance and use of either protease inhibitors or nonnucleoside drugs, but did discover that patients who began anti-HIV therapy with low CD4-cell counts were also at a higher risk for the condition. The study concurs with an earlier study of U.S. women that also found no connection between protease inhibitor of nonnuke use and insulin resistance. A study reported in the October 2005 issue of HIV Plus shows that men taking anti-HIV medications have a 4.6-fold greater risk of developing diabetes than their untreated peers. A study reported in the August 2005 issue of HIV Plus suggests that antiretroviral regimens that do not contain a protease inhibitor might put HIV-positive women at more than double the risk of developing insulin resistance.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Don’t miss our latest news! Sign up today for our free newsletter.
Plus: Featured Video
Latest Stories
‘Kokomo City’ Gives a Searing Look Into Lives of Black Trans Sex Workers
August 18 2023 12:40 PM